HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.

[1]  N. Weidner,et al.  Her2 Amplification: Correlation of Chromogenic In Situ Hybridization With Immunohistochemistry and Fluorescence In Situ Hybridization , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[2]  J. Isola,et al.  Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization , 2004, Clinical Cancer Research.

[3]  O. Dietze,et al.  Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer. , 2004, Anticancer research.

[4]  J. Vera-Román,et al.  Comparative assays for the HER-2/neu oncogene status in breast cancer. , 2004, Archives of pathology & laboratory medicine.

[5]  N. Sneige,et al.  The Use of TMA for Interlaboratory Validation of FISH Testing for Detection of HER2 Gene Amplification in Breast Cancer , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  M. Owens,et al.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.

[7]  M. Weinstein,et al.  HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Alsabeh,et al.  Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. , 2004, American journal of clinical pathology.

[9]  F. Penault-llorca,et al.  Recherche de l'amplification du gène HER2: la CISH est-elle une alternative à la technique FISH? , 2003 .

[10]  H. Tsuda,et al.  Interlaboratory Comparison in HercepTest Assessment of HER2 Protein Status in Invasive Breast Carcinoma Fixed With Various Formalin-based Fixatives , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[11]  C. Cohen,et al.  Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. , 2003, Human pathology.

[12]  A. Sapino,et al.  Which breast carcinomas need HER‐2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c‐erbB2 protein domains , 2003, Histopathology.

[13]  A. Vincent-Salomon,et al.  Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer , 2003, British Journal of Cancer.

[14]  A. Vincent-Salomon,et al.  Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS * Study , 2003, Histopathology.

[15]  J. Bartlett,et al.  The clinical evaluation of HER‐2 status: which test to use? , 2003, The Journal of pathology.

[16]  M. Dowsett,et al.  Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres , 2003, The Journal of pathology.

[17]  L. Middleton,et al.  Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. , 2003, American journal of clinical pathology.

[18]  J. Bartlett,et al.  Molecular diagnostics for determination of HER2 status in breast cancer , 2003 .

[19]  Hung Chiang,et al.  Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. , 2002, American journal of clinical pathology.

[20]  Anthony Rhodes,et al.  Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. , 2002, American journal of clinical pathology.

[21]  O. Dietze,et al.  Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma , 2002, Laboratory Investigation.

[22]  Jinha M. Park,et al.  Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Au,et al.  Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma , 2002, Modern Pathology.

[24]  J. Beneke,et al.  HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. , 2002, American journal of clinical pathology.

[25]  H. Tsuda,et al.  Evaluation of interobserver agreement in scoring immunohistochemical results of HER‐2/neu (c‐erbB‐2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma , 2002, Pathology international.

[26]  E. Frenkel,et al.  Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status , 2002, Modern Pathology.

[27]  Y. Oda,et al.  Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. , 2002, Human pathology.

[28]  F. Kokocinski,et al.  Automated Screening for Genomic Imbalances using Matrix-Based Comparative Genomic Hybridization , 2002, Laboratory Investigation.

[29]  H. Tsuda,et al.  Detection of HER‐2/neu (c‐erb B‐2) DNA amplification in primary breast carcinoma , 2001, Cancer.

[30]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.

[31]  E. Campo,et al.  Tissue macroarrays ("microchops") for gene expression analysis , 2001, Virchows Archiv.

[32]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Tsuda,et al.  Concordance in judgments among c‐erbB‐2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma , 2001, Pathology international.

[34]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Larsimont,et al.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.

[36]  R. Ridolfi,et al.  HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.

[37]  N. Sneige,et al.  HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. , 2000, American journal of clinical pathology.

[38]  A. Sahin.  Biologic and Clinical Significance of HER‐2/neu (cerbB‐2) in Breast Cancer , 2000, Advances in anatomic pathology.

[39]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Fletcher,et al.  The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.

[41]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[43]  R Akita,et al.  Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.

[44]  D. Horsfall,et al.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Fourney,et al.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.